GLAXO Relative Valuation - GlaxoSmithKline Pharmaceuticals Ltd

Watchlist Manager

Watchlist

Price: 2 375.2 INR 1.79%

Market Cap: ₹402.4B

	GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO	IN

Multiples-Based Value

The Multiples-Based Value for GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) under the Base Case is 1 995.67 INR. Compared with the current market price of 2 375.2 INR, the stock appears Overvalued by 16%.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

What is relative valuation?

How is Multiples-Based Value calculated?

GLAXO Multiples-Based Value

Base Case

Overvaluation 16%

Multiples-Based Value

Price ₹2 375.2

Worst Case

Base Case

Best Case

Valuation Multiples

View Details

Multiples Across Competitors

All Multiples

P/S

P/E

EV/EBITDA

EV/EBIT

Forward Multiples

			Market Cap	P/S	P/E	EV/EBITDA	EV/EBIT
IN		GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO	395.3B INR	10.6	39.5	28.9	31.2
US		Eli Lilly and Co NYSE:LLY	879.7B USD	13.5	42.6	28.8	30.7
US		Johnson & Johnson NYSE:JNJ	574.1B USD	6.1	21.4	14.9	18.3
CH		Roche Holding AG SIX:ROG	248.4B CHF	4.1	19.7	11.6	13.1
UK		AstraZeneca PLC LSE:AZN	232B GBP	5.2	30	16.6	23.4
US		Merck & Co Inc NYSE:MRK	295.2B USD	4.5	16.2	10	12.2
CH		Novartis AG SIX:NOVN	236.4B CHF	5.1	20.6	12.7	16.4
IE	E	Endo International PLC LSE:0Y5F	244.4B USD	105.4	-83.6	386.8	970
DK		Novo Nordisk A/S CSE:NOVO B	1.1T DKK	3.4	10.2	7.6	8.9
US		Pfizer Inc NYSE:PFE	154.1B USD	2.5	19.8	7.6	10.2
US		Bristol-Myers Squibb Co NYSE:BMY	116.1B USD	2.4	16.5	7	8.6

				Revenue Growth	P/S to Growth
IN		GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO	Average P/S: 14.8 10.6	9%	1.2
US		Eli Lilly and Co NYSE:LLY	13.5	19%	0.7
US		Johnson & Johnson NYSE:JNJ	6.1	7%	0.9
CH		Roche Holding AG SIX:ROG	4.1	4%	1
UK		AstraZeneca PLC LSE:AZN	5.2	N/A	N/A
US		Merck & Co Inc NYSE:MRK	4.5	5%	0.9
CH		Novartis AG SIX:NOVN	5.1	5%	1
IE	E	Endo International PLC LSE:0Y5F	105.4	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	3.4	1%	3.4
US		Pfizer Inc NYSE:PFE	2.5	-4%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	2.4	-5%	N/A

				Earnings Growth	PEG
IN		GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO	Average P/E: 23.6 39.5	14%	2.8
US		Eli Lilly and Co NYSE:LLY	42.6	32%	1.3
US		Johnson & Johnson NYSE:JNJ	21.4	7%	3.1
CH		Roche Holding AG SIX:ROG	19.7	14%	1.4
UK		AstraZeneca PLC LSE:AZN	30	26%	1.2
US		Merck & Co Inc NYSE:MRK	16.2	14%	1.2
CH		Novartis AG SIX:NOVN	20.6	14%	1.5
IE	E	Endo International PLC LSE:0Y5F	Negative Multiple: -83.6	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	10.2	1%	10.2
US		Pfizer Inc NYSE:PFE	19.8	22%	0.9
US		Bristol-Myers Squibb Co NYSE:BMY	16.5	16%	1

				EBITDA Growth	EV/EBITDA to Growth
IN		GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO	Average EV/EBITDA: 48.4 28.9	13%	2.2
US		Eli Lilly and Co NYSE:LLY	28.8	22%	1.3
US		Johnson & Johnson NYSE:JNJ	14.9	2%	7.4
CH		Roche Holding AG SIX:ROG	11.6	6%	1.9
UK		AstraZeneca PLC LSE:AZN	16.6	13%	1.3
US		Merck & Co Inc NYSE:MRK	10	3%	3.3
CH		Novartis AG SIX:NOVN	12.7	5%	2.5
IE	E	Endo International PLC LSE:0Y5F	386.8	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	7.6	1%	7.6
US		Pfizer Inc NYSE:PFE	7.6	-9%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	7	-10%	N/A

				EBIT Growth	EV/EBIT to Growth
IN		GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO	Average EV/EBIT: 103.9 31.2	13%	2.4
US		Eli Lilly and Co NYSE:LLY	30.7	22%	1.4
US		Johnson & Johnson NYSE:JNJ	18.3	6%	3
CH		Roche Holding AG SIX:ROG	13.1	6%	2.2
UK		AstraZeneca PLC LSE:AZN	23.4	21%	1.1
US		Merck & Co Inc NYSE:MRK	12.2	6%	2
CH		Novartis AG SIX:NOVN	16.4	9%	1.8
IE	E	Endo International PLC LSE:0Y5F	970	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	8.9	2%	4.4
US		Pfizer Inc NYSE:PFE	10.2	-4%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	8.6	-7%	N/A

GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO

Multiples-Based Value

Valuation Multiples

Multiples Across Competitors

GLAXO Competitors Multiples
GlaxoSmithKline Pharmaceuticals Ltd Competitors

See Also

Company

Help

Tools

Stocks

GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO

Multiples-Based Value

Valuation Multiples

Multiples Across Competitors

GLAXO Competitors Multiples GlaxoSmithKline Pharmaceuticals Ltd Competitors

See Also

Company

Help

Tools

Stocks

GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO

GLAXO Competitors Multiples
GlaxoSmithKline Pharmaceuticals Ltd Competitors